{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:56:57Z","timestamp":1788623817024,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["#25461571"],"award-info":[{"award-number":["#25461571"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP17ek0109088, JP19ek0109336"],"award-info":[{"award-number":["JP17ek0109088, JP19ek0109336"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Growth differentiation factor 15 (GDF15) has been reported to be associated with fibrosis and cancer in liver disease. Diagnosis of autoimmune hepatitis (AIH) is often difficult because of the lack of specific markers. We investigated whether GDF15 is useful for diagnosing AIH and determined its therapeutic effects. We enrolled 171 Japanese patients as follows: AIH (n\u2009=\u200945), hepatitis B (HB) (n\u2009=\u200917), hepatitis C (HC) (n\u2009=\u200915), primary biliary cholangitis (PBC) (n\u2009=\u200920), and 74 healthy controls. Serum GDF15 levels were measured, and immunohistological analyses of GDF15 were performed using liver tissue of AIH patients. (1) GDF15 levels (pg\/ml) were higher in AIH (1994.3\u2009\u00b1\u20091258.0) and HC (1568.0\u2009\u00b1\u2009822.3) than in HB (953.2\u2009\u00b1\u2009871.4), PBC (643.9\u2009\u00b1\u2009247.0), and controls (475.3\u2009\u00b1\u2009145.3) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), as well as in cirrhosis patients (n\u2009=\u200931) than in non-cirrhosis patients (n\u2009=\u200966) (1926.6\u2009\u00b1\u20091026.0 vs. 1249.1\u2009\u00b1\u20091124.1, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In non-cirrhosis patients, GDF15 levels were higher in AIH (1914.0\u2009\u00b1\u20091327.2) than in HC (955.7\u2009\u00b1\u2009502.7), HB (519.3\u2009\u00b1\u2009197.5), and PBC (643.9\u2009\u00b1\u2009247.0) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). (2) GDF15 was positively correlated with M2BPGi (r\u2009=\u20090.7728), total bilirubin (r\u2009=\u20090.6231), and PT-INR (r\u2009=\u20090.6332). (3) GDF15 levels could be used to distinguish AIH from other liver diseases in non-cirrhosis patients, with an area under the curve of 0.9373 (sensitivity 93.6%, specificity 79.3%, cut-off value 931.3). (4) GDF15 in AIH decreased after treatment. (5) Immunohistological analyses in AIH liver tissues revealed that GDF15 was strongly expressed in inflammatory cells, hepatic cytoplasm, and sinusoidal endothelial cells, but decreased after treatment. GDF15 is a novel diagnostic marker for AIH and is also expected to be a therapeutic marker for AIH.<\/jats:p><jats:p>Clinical Trials Registration: The study protocol was approved by the institutional review board of Kurume University (Approval No.: 19049).<\/jats:p>","DOI":"10.1038\/s41598-022-12762-9","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T15:03:54Z","timestamp":1653404634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis"],"prefix":"10.1038","volume":"12","author":[{"given":"Teruko","family":"Arinaga-Hino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiichiro","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Mitsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Torimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"12762_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack, C. L. et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice guidance and guidelines from the American association for the study of liver diseases. Hepatology 72, 671\u2013722 (2020).","journal-title":"Hepatology"},{"key":"12762_CR2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez, F. et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 31, 929\u2013938 (1999).","journal-title":"J Hepatol."},{"key":"12762_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes, E. M. et al. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 48, 169\u201376 (2008).","journal-title":"Hepatology."},{"key":"12762_CR4","unstructured":"Clinical Practice Guidelines for Autoimmune Hepatitis (AIH) (2016). The intractable hepatobiliary disease study group supported by the Ministry of Health, Labor and Welfare of Japan. http:\/\/www.hepatobiliary.jp\/modules\/medical\/index.php?content_id=14"},{"key":"12762_CR5","doi-asserted-by":"publisher","first-page":"14250","DOI":"10.1038\/s41598-020-71296-0","volume":"10","author":"A Takahashi","year":"2020","unstructured":"Takahashi, A. et al. Increasing incidence of acute autoimmune hepatitis: A nationwide survey in Japan. Sci. Rep. 10, 14250 (2020).","journal-title":"Sci. Rep."},{"key":"12762_CR6","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.jhepr.2020.100149","volume":"2","author":"MN Rahim","year":"2020","unstructured":"Rahim, M. N., Miquel, R. & Heneghan, M. A. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep. 2, 100149 (2020).","journal-title":"JHEP Rep."},{"key":"12762_CR7","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.23588","volume":"51","author":"E Bjornsson","year":"2010","unstructured":"Bjornsson, E. et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 51, 2040\u20132048 (2010).","journal-title":"Hepatology"},{"key":"12762_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00535-015-1131-7","volume":"51","author":"A Hisamochi","year":"2016","unstructured":"Hisamochi, A. et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J. Gastroenterol. 51, 597\u2013607 (2016).","journal-title":"J. Gastroenterol."},{"key":"12762_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","volume":"394","author":"RT Stravitz","year":"2019","unstructured":"Stravitz, R. T. & Lee, W. M. Acute liver failure. Lancet 394, 869\u2013881 (2019).","journal-title":"Lancet"},{"key":"12762_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/hepr.13342","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka, A. et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol. Res. 49, 881\u2013889 (2019).","journal-title":"Hepatol. Res."},{"key":"12762_CR11","first-page":"1022","volume":"52","author":"B\u00c5 Danielsson","year":"2017","unstructured":"Danielsson, B. \u00c5. et al. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scand. J. Gastroenterol. 52, 1022\u20131028 (2017).","journal-title":"Scand. J. Gastroenterol."},{"key":"12762_CR12","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/jgh.14746","volume":"34","author":"T Lv","year":"2019","unstructured":"Lv, T. et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J. Gastroenterol. Hepatol. 34, 1676\u20131684 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"12762_CR13","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","volume":"94","author":"MR Bootcov","year":"1997","unstructured":"Bootcov, M. R. et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. U.S.A 94, 11514\u201311519 (1997).","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"12762_CR14","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1128\/MCB.20.10.3742-3751.2000","volume":"20","author":"EC Hsiao","year":"2000","unstructured":"Hsiao, E. C. et al. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol. Cell. Biol. 20, 3742\u20133751 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"12762_CR15","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.24506","volume":"78","author":"S Yatsuga","year":"2015","unstructured":"Yatsuga, S. et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 78, 814\u2013823 (2015).","journal-title":"Ann Neurol."},{"key":"12762_CR16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/jcmm.12830","volume":"20","author":"C Li","year":"2016","unstructured":"Li, C. et al. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J. Cell. Mol. Med. 20, 1420\u20131426 (2016).","journal-title":"J. Cell. Mol. Med."},{"key":"12762_CR17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.109.928846","volume":"122","author":"IS Anand","year":"2010","unstructured":"Anand, I. S. et al. Serial measurement of growth-differentiation factor-15 in heart failure: Relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122, 1387\u20131395 (2010).","journal-title":"Circulation"},{"key":"12762_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1530\/EJE-09-0417","volume":"161","author":"I Dost\u00e1lov\u00e1","year":"2009","unstructured":"Dost\u00e1lov\u00e1, I. et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: The influence of very low calorie diet. Eur. J. Endocrinol. 161, 397\u2013404 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"12762_CR19","doi-asserted-by":"publisher","first-page":"e19967","DOI":"10.1371\/journal.pone.0019967","volume":"6","author":"Y Si","year":"2011","unstructured":"Si, Y. et al. Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes. PLoS ONE 6, e19967 (2011).","journal-title":"PLoS ONE"},{"key":"12762_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/liv.13587","volume":"38","author":"BK Koo","year":"2018","unstructured":"Koo, B. K. et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 38, 695\u2013705 (2018).","journal-title":"Liver Int."},{"key":"12762_CR21","first-page":"5162541","volume":"2020","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Association between circulating growth differentiation factor 15 and cirrhotic primary biliary cholangitis. Biomed. Res. Int. 2020, 5162541 (2020).","journal-title":"Biomed. Res. Int."},{"key":"12762_CR22","unstructured":"Clinical Practice Guidelines for Primary Biliary Cholangitis (PBC) (2017): The intractable hepatobiliary disease study group supported by the Ministry of Health, Labor and Welfare of Japan. http:\/\/www.hepatobiliary.jp\/modules\/medical\/index.php?content_id=14"},{"key":"12762_CR23","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/hep.1840190629","volume":"19","author":"VJ Desmet","year":"1994","unstructured":"Desmet, V. J., Gerber, M., Hoofnagle, J. H., Manns, M. & Scheuer, P. J. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19, 1513\u20131520 (1994).","journal-title":"Hepatology"},{"key":"12762_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.22410","volume":"56","author":"DA Brown","year":"2007","unstructured":"Brown, D. A. et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: A potential marker of erosive joint destruction. Arthritis Rheum. 56, 753\u2013764 (2007).","journal-title":"Arthritis Rheum."},{"key":"12762_CR25","doi-asserted-by":"publisher","first-page":"116429","DOI":"10.1016\/j.jns.2019.116429","volume":"405","author":"S Nohara","year":"2019","unstructured":"Nohara, S. et al. GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis. J. Neurol. Sci. 405, 116429 (2019).","journal-title":"J. Neurol. Sci."},{"key":"12762_CR26","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1681\/ASN.2016080919","volume":"28","author":"V Nair","year":"2017","unstructured":"Nair, V. et al. Growth differentiation factor-15 and risk of CKD progression. J. Am. Soc. Nephrol. 28, 2233\u20132240 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"12762_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","volume":"178","author":"HH Luan","year":"2019","unstructured":"Luan, H. H. et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell 178, 1231\u20131244 (2019).","journal-title":"Cell"},{"key":"12762_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/hepr.12931","volume":"47","author":"K Harada","year":"2017","unstructured":"Harada, K., Hiep, N. C. & Ohira, H. Challenges and difficulties in pathological diagnosis of autoimmune hepatitis. Hepatol. Res. 47, 963\u2013971 (2017).","journal-title":"Hepatol. Res."},{"key":"12762_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000440747","volume":"33","author":"DG Tiniakos","year":"2015","unstructured":"Tiniakos, D. G., Brain, J. G. & Bury, Y. A. Role of histopathology in autoimmune hepatitis. Dig. Dis. 33, 53\u201364 (2015).","journal-title":"Dig. Dis."},{"key":"12762_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/apt.12592","volume":"39","author":"AJ Czaja","year":"2014","unstructured":"Czaja, A. J. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol. Ther. 39, 385\u2013406 (2014).","journal-title":"Aliment Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12762-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:31:04Z","timestamp":1669347064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12762-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12762"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12762-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8759"}}